PT-141 (Bremelanotide)
A cyclic heptapeptide derived from Melanotan II and a melanocortin receptor agonist. PT-141 acts centrally via MC3R and MC4R pathways rather than through the vascular system, making it a unique research tool for studying central mechanisms of arousal, motivation, and melanocortin signalling.
Research Use Only. PT-141 (Bremelanotide) is sold exclusively for in vitro research and laboratory use by qualified scientists. Not for human consumption, veterinary use, or clinical administration.
Research Literature
Published Research
PT-141 acts centrally via melanocortin MC3R/MC4R pathways, providing a unique research tool for central arousal and motivation circuitry studies.
PT-141: a melanocortin agonist for sexual dysfunction
Key finding: Central MC4R activation produces arousal response independent of vascular mechanisms.
PubMed 15170097 ↗Bremelanotide mechanism of action studies
Key finding: Direct CNS activation via hypothalamic melanocortin pathways confirmed in rodent and primate models.
PubMed 16614727 ↗Phase III clinical outcomes for bremelanotide
Key finding: Significant improvement in desire and distress scores confirmed central mechanism efficacy.
PubMed 28467713 ↗Same Category